Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.
OBJECTIVE
Two cases of penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angio-tensin II receptor blockers are reported.


CONCLUSIONS
The first case of penile angioe-dema involved a 68-year-old man who arrived at the emergency department (ED) with a 2-12-hour history of penile swelling occurring three days after initiation of irbesartan in addition to longstanding lisinopril therapy. All parts of the physical examination were normal, except for the genital examination. The patient's penis was edematous at midshaft only and was nontender with normal skin coloring. The edema was nonpitting and limited to the skin. The patient was instructed to stop taking both lisinopril and irbesartan, and symptoms resolved within 48 hours with supportive care alone. In the second case, a 48-year-old man arrived at the ED complaining of penile swelling over the previous two days. Enalapril had been initiated one month before his arrival at the ED. The patient's penis was nontender and edematous at midshaft. The edema was nonpitting and limited to the skin. The patient was instructed to stop taking enalapril, given oral prednisone 60 mg, and asked to continue his prednisone for five days after discharge. The swelling resolved within two days of stopping enalapril, and he had no further episodes of penile swelling. Neither patient was rechallenged with the offending medications.


CONCLUSIONS
Penile angioedema was reported in two patients. The first case involved a patient receiving both lisinopril and irbesartan. The second patient was receiving enalapril only.
McCabe
John
J
Department of Emergency Medicine, State University of New York Upstate Medical University, Syracuse, USA.
Stork
Christine
C
Mailloux
Danielle
D
Su
Mark
M
D000368:Aged; D000799:Angioedema / Q000139:chemically induced*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001713:Biphenyl Compounds / Q000009:adverse effects; D004656:Enalapril / Q000009:adverse effects; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000077405:Irbesartan; D017706:Lisinopril / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010413:Penis / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D013777:Tetrazoles / Q000009:adverse effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D005938:Glucocorticoids; D013777:Tetrazoles; D004656:Enalapril; D017706:Lisinopril; D000077405:Irbesartan; D011241:Prednisone